Cancer Research and Treatment

Original Articles

Clinical Significance of Pleural Attachment and Indentation of Subsolid Nodule Lung Cancer: Hyung-Jun Kim, Jun Yeun Cho, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Jin-Haeng Chung, Sukki Cho, Kwhanmien Kim, Kyung Won Lee, Jae Ho Lee, Choon-Taek Lee; Cancer Res Treat. 2019;51(4):1540-1548. Published online March 25, 2019; DOI: https://doi.org/10.4143/crt.2019.057

Abstract PDF Supplementary Material PubReader ePub

Purpose
Lung cancers presenting as subsolid nodule commonly have peripheral location, making the cancer-pleura relationship noteworthy. We aimed to evaluate the effect of pleural attachment and/or indentation on visceral pleural invasion (VPI) and recurrence-free survival.
Materials and Methods
Patients who underwent curative resection of lung cancer as subsolid nodules from April 2007 to January 2016 were retrospectively evaluated. They were divided into four groups according to their relationship with the pleura. Clinical, radiographical, and pathological findings were analyzed.
Results
Among 404 patients with malignant subsolid nodule, 120 (29.7%) had neither pleural attachment nor indentation, 26 (6.4%) had attachment only, 117 (29.0%) had indentation only, and 141 (34.9%) had both. VPI was observed in nodules of 36 patients (8.9%), but absent in nonsolid nodules and in those without pleural attachment and/or indentation. Compared to subsolid nodules with concurrent pleural attachment and indentation, those with attachment only (odds ratio, 0.12; 95% confidence interval [CI], 0.02 to 0.98) and indentation only (odds ratio, 0.10; 95% CI, 0.03 to 0.31) revealed lower odds of VPI. On subgroup analysis, the size of the solid portion was associated with VPI among those with pleural attachment and indentation (p=0.021). Such high-risk features for VPI were associated with earlier lung cancer recurrence (adjusted hazard ratio, 3.31; 95% CI, 1.58 to 6.91).
Conclusion
Concurrent pleural attachment and indentation are risk factors for VPI, and the odds increase with larger solid portion in subsolid nodules. Considering the risk of recurrence, early surgical resection could be encouraged in these patients.

Citations

Citations to this article as recorded by

A CT-based deep learning model: visceral pleural invasion and survival prediction in clinical stage IA lung adenocarcinoma
Xiaofeng Lin, Kunfeng Liu, Kunwei Li, Xiaojuan Chen, Biyun Chen, Sheng Li, Huai Chen, Li Li
iScience.2024; 27(1): 108712. CrossRef
CT-Based Intratumoral and Peritumoral Radiomics Nomograms for the Preoperative Prediction of Spread Through Air Spaces in Clinical Stage IA Non-small Cell Lung Cancer
Yun Wang, Deng Lyu, Lei Hu, Junhong Wu, Shaofeng Duan, Taohu Zhou, Wenting Tu, Yi Xiao, Li Fan, Shiyuan Liu
Journal of Imaging Informatics in Medicine.2024; 37(2): 520. CrossRef
Prognostic Analysis of Stage I Non-Small Cell Lung Cancer Abutting Adjacent Structures on Preoperative Computed Tomography
Soohwan Choi, Sun Kyun Ro, Seok Whan Moon
Journal of Chest Surgery.2024; 57(2): 136. CrossRef
Nomogram using intratumoral and peritumoral radiomics for the preoperative prediction of visceral pleural invasion in clinical stage IA lung adenocarcinoma
Yun Wang, Deng Lyu, Su Hu, Yanqing Ma, Shaofeng Duan, Yayuan Geng, Taohu Zhou, Wenting Tu, Yi Xiao, Li Fan, Shiyuan Liu
Journal of Cardiothoracic Surgery.2024;[Epub] CrossRef
Nomogram for predicting invasive lung adenocarcinoma in small solitary pulmonary nodules
Mengchao Xue, Rongyang Li, Junjie Liu, Ming Lu, Zhenyi Li, Huiying Zhang, Hui Tian
Frontiers in Oncology.2024;[Epub] CrossRef
Analysis of postoperative recurrence-free survival in non–small cell lung cancer patients based on consensus clustering
Q. Tian, S.-Y. Zhou, Y.-H. Qin, Y.-Y. Wu, C. Qin, H. Zhou, J. Shi, S.-F. Duan, F. Feng
Clinical Radiology.2024; 79(10): e1214. CrossRef
Predicting bone metastasis-free survival in non-small cell lung cancer from preoperative CT via deep learning
Jia Guo, Jianguo Miao, Weikai Sun, Yanlei Li, Pei Nie, Wenjian Xu
npj Precision Oncology.2024;[Epub] CrossRef
The prognostic value of visceral pleural infiltration in ≤3 cm nonsmall cell lung cancer presenting with ground glass opacity: an inverse probability of treatment weighting study
Zhenyu Yang, Yiming Li, Chenglin Guo, Yikai Xing, Chengwu Liu, Jian Zhang, Qiang Pu, Lunxu Liu
International Journal of Surgery.2024; 110(12): 7871. CrossRef
Tumour–pleura relationship on CT is a risk factor for occult lymph node metastasis in peripheral clinical stage IA solid adenocarcinoma
Chengzhou Zhang, Liping Wang, Xiaoting Cai, Mengfei Li, Dandan Sun, Ping Wang
European Radiology.2023; 33(5): 3083. CrossRef
Analysis of the relevance between computed tomography characterization and pathology of pulmonary ground-glass nodules with different pathology types
Zhang Youguo, Wang Chengye, Cheng Xiaofei, Zhang Xuefei, Liu Changhong
Turkish Journal of Thoracic and Cardiovascular Surgery.2023; 31(1): 95. CrossRef
Risk factors for loss of pulmonary function after wedge resection for peripheral ground-glass opacity dominant lung cancer
Tomohiro Miyoshi, Hiroyuki Ito, Masashi Wakabayashi, Tadayoshi Hashimoto, Yuta Sekino, Kenji Suzuki, Masahiro Tsuboi, Yasumitsu Moriya, Ichiro Yoshino, Tetsuya Isaka, Aritoshi Hattori, Takahiro Mimae, Mitsuhiro Isaka, Tomohiro Maniwa, Makoto Endo, Hiroshi
European Journal of Cardio-Thoracic Surgery.2023;[Epub] CrossRef
Volumetric analysis of intravoxel incoherent motion diffusion-weighted imaging in preoperative assessment of non-small cell lung cancer
Jianqin Jiang, Yigang Fu, Lili Zhang, Jia Liu, Xiaowen Gu, Weiwei Shao, Lei Cui, Gaofeng Xu
Japanese Journal of Radiology.2022; 40(9): 903. CrossRef
A Nomogram Combined Radiomics and Clinical Features as Imaging Biomarkers for Prediction of Visceral Pleural Invasion in Lung Adenocarcinoma
Xinyi Zha, Yuanqing Liu, Xiaoxia Ping, Jiayi Bao, Qian Wu, Su Hu, Chunhong Hu
Frontiers in Oncology.2022;[Epub] CrossRef
Radiologists with and without deep learning–based computer-aided diagnosis: comparison of performance and interobserver agreement for characterizing and diagnosing pulmonary nodules/masses
Tomohiro Wataya, Masahiro Yanagawa, Mitsuko Tsubamoto, Tomoharu Sato, Daiki Nishigaki, Kosuke Kita, Kazuki Yamagata, Yuki Suzuki, Akinori Hata, Shoji Kido, Noriyuki Tomiyama
European Radiology.2022; 33(1): 348. CrossRef
The value of CT radiomics features to predict visceral pleural invasion in ≤3 cm peripheral type early non-small cell lung cancer
Shu-Hua Wei, Jin-Mei Zhang, Bin Shi, Fei Gao, Zhao-Xuan Zhang, Li-Ting Qian
Journal of X-Ray Science and Technology.2022; 30(6): 1115. CrossRef
Pathological components and CT imaging analysis of the area adjacent pleura within the pure ground-glass nodules with pleural deformation in invasive lung adenocarcinoma
Yining Jiang, Ziqi Xiong, Wenjing Zhao, Di Tian, Qiuping Zhang, Zhiyong Li
BMC Cancer.2022;[Epub] CrossRef
Development and validation of a deep learning signature for predicting lymph node metastasis in lung adenocarcinoma: comparison with radiomics signature and clinical-semantic model
Xiaoling Ma, Liming Xia, Jun Chen, Weijia Wan, Wen Zhou
European Radiology.2022; 33(3): 1949. CrossRef
Lung-RADS Version 1.1: Challenges and a Look Ahead, From the AJR Special Series on Radiology Reporting and Data Systems
Lydia Chelala, Rydhwana Hossain, Ella A. Kazerooni, Jared D. Christensen, Debra S. Dyer, Charles S. White
American Journal of Roentgenology.2021; 216(6): 1411. CrossRef
Predicting pathological lymph node status in clinical stage IA peripheral lung adenocarcinoma
Keiju Aokage, Kenji Suzuki, Masashi Wakabayashi, Tomonori Mizutani, Aritoshi Hattori, Haruhiko Fukuda, Shun-Ichi Watanabe
European Journal of Cardio-Thoracic Surgery.2021; 60(1): 64. CrossRef
Discriminating Small-Sized (2 cm or Less), Noncalcified, Solitary Pulmonary Tuberculoma and Solid Lung Adenocarcinoma in Tuberculosis-Endemic Areas
Jingping Zhang, Tingting Han, Jialiang Ren, Chenwang Jin, Ming Zhang, Youmin Guo
Diagnostics.2021; 11(6): 930. CrossRef
Association of postoperative recurrence with radiological and clinicopathological features in patients with stage IA–IIA lung adenocarcinoma
Yanyan Zhang, Fengnian Zhao, Minghao Wu, Yunqing Zhao, Ying Liu, Qian Li, Guiming Zhou, Zhaoxiang Ye
European Journal of Radiology.2021; 141: 109802. CrossRef
Characterization of Newly Detected Costal Pleura–attached Noncalcified Nodules at Annual Low-Dose CT Screenings
Yeqing Zhu, Rowena Yip, Nan You, Qiang Cai, Claudia I. Henschke, David F. Yankelevitz, Claudia I. Henschke, David F. Yankelevitz, Rowena Yip, Dongming Xu, Mary Salvatore, Raja Flores, Andrea Wolf, David S. Mendelson, Dorothy I. McCauley, Mildred Chen, Dan
Radiology.2021; 301(3): 724. CrossRef
Clinicopathological and computed tomographic features associated with occult lymph node metastasis in patients with peripheral solid non-small cell lung cancer
Xiao-Qun He, Tian-You Luo, Xian Li, Ji-Wen Huo, Jun-Wei Gong, Qi Li
European Journal of Radiology.2021; 144: 109981. CrossRef
Surgical Extent for Ground Glass Nodules
Suk Ki Cho
Journal of Chest Surgery.2021; 54(5): 338. CrossRef
CT-guided microcoil localization for pulmonary nodules before VATS: a retrospective evaluation of risk factors for pleural marking failure
Yanyan Xu, Lingchuan Ma, Hongliang Sun, Zhenguo Huang, Zhenrong Zhang, Fei Xiao, Qianli Ma, Chuandong Li, Xiaomeng Zhang, Sheng Xie
European Radiology.2020; 30(10): 5674. CrossRef
Management of Nodules Attached to the Costal Pleura at Low-Dose CT Screening for Lung Cancer
Yeqing Zhu, Rowena Yip, Nan You, Claudia I. Henschke, David F. Yankelevitz
Radiology.2020; 297(3): 710. CrossRef

9,632 View
212 Download
32 Web of Science
26 Crossref

Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model: Hyo Joon Jang, Sukki Cho, Kwhanmien Kim, Sanghoon Jheon, Hee Chul Yang, Dong Kwan Kim; Cancer Res Treat. 2017;49(4):898-905. Published online January 18, 2017; DOI: https://doi.org/10.4143/crt.2016.312

Abstract PDF PubReader ePub

Purpose
We conducted a retrospective analysis to determine if adjuvant chemotherapy prolongs overall survival in patients with pathologic stage IB lung adenocarcinoma who had undergone complete resection and were defined as high-risk by a newly developed recurrence risk scoring model.
Materials and Methods
Patientswho underwent curative resection for stage IB lung adenocarcinomawere analyzed with a newly developed recurrence risk scoring model and divided into a low-risk group and a high-risk group. The patients in the high-risk group were retrospectively divided into two groups based on whether they underwent adjuvant chemotherapy or observation. Recurrence-free survival and overall survival were compared between these two groups.
Results
A total of 328 patients who underwent curative resection between 2000 and 2009 were included in this study, of whom 110 (34%) received adjuvant chemotherapy and 218 (67%) underwent observation without additional treatment. According to our risk model, 167 patients (51%) were high-risk and 161 (49%) were low-risk. The 5-year recurrence-free survival rates and overall survival were 84.4% and 91.5% in low-risk patients and 53.9% and 74.7% in high-risk patients (p < 0.001). In high-risk patients, the 5-year overall survival rates were 77% among patients who underwent observation and 87% among those who underwent adjuvant chemotherapy (p=0.019).
Conclusion
Adjuvant chemotherapy prolonged overall survival among high-risk patients who had undergone complete resection for stage IB lung adenocarcinoma.

Citations

Citations to this article as recorded by

Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
Zi-Qing Shen, Kun-Peng Feng, Zi-Yao Fang, Tian Xia, Shu Pan, Cheng Ding, Chun Xu, Sheng Ju, Jun Chen, Chang Li, Jun Zhao
Journal of Cardiothoracic Surgery.2024;[Epub] CrossRef
Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study
Monica Casiraghi, Francesco Petrella, Claudia Bardoni, Shehab Mohamed, Giulia Sedda, Juliana Guarize, Antonio Passaro, Filippo De Marinis, Patrick Maisonneuve, Lorenzo Spaggiari
Journal of Clinical Medicine.2023; 12(5): 2081. CrossRef
A Novel Nomogram for Identifying Candidates for Adjuvant Chemotherapy in Patients With Stage IB Non-small Cell Lung Cancer
Xue Song, Yangyang Xie, Haoran Deng, Fei Yu, Shiqiang Wang, Yafang Lou
Cancer Control.2023;[Epub] CrossRef
Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis
Ke Zhou, Yaqin Zhao, Linchuan Liang, Jie Cao, Huahang Lin, Zhiyu Peng, Jiandong Mei
Frontiers in Oncology.2022;[Epub] CrossRef
A Population-Based Study on the Prognostic factors and Efficacy of Adjuvant Chemotherapy in the Postoperative Stage for Patients with Stage IIA Non-Small Cell Lung Cancer
Wei Wang, Fei Teng, Shi Bu, Wei Xu, Qing-Chun Cai, Yue-Quan Jiang, Zhi-Qiang Wang
Risk Management and Healthcare Policy.2022; Volume 15: 1581. CrossRef
Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer
Matvey M. Tsyganov, Evgeny O. Rodionov, Marina K. Ibragimova, Sergey V. Miller, Olga V. Cheremisina, Irina G. Frolova, Sergey A. Tuzikov, Nikolai V. Litviakov
Journal of Personalized Medicine.2022; 12(10): 1647. CrossRef
Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort
Zhichao Zuo, Guochao Zhang, Peng Song, Jing Yang, Shuiting Li, Zhi Zhong, Qinghao Tan, Liming Wang, Qi Xue, Shugeng Gao, Nan Sun, Jie He
Annals of Surgical Oncology.2021; 28(7): 3941. CrossRef
Drug Regimen for Patients after a Pneumonectomy
Noheul Kim, Ronny Priefer
Journal of Respiration.2021; 1(2): 114. CrossRef
Prognostic stratification of pathological node-negative lung adenocarcinoma by carcinoembryonic antigen level
Khashchuluun Batmunkh, Sukki Cho, Sungwon Yum, Kwhanmien Kim, Sanghoon Jheon
Interactive CardioVascular and Thoracic Surgery.2020; 30(6): 820. CrossRef
Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion
Jun Xie, Xian Zhang, Song Hu, Wan-Da Peng, Bin Xu, Yan Li, Su-Juan Zhang, Qing Li, Chong Li
Journal of Cancer Research and Clinical Oncology.2020; 146(9): 2231. CrossRef

8,477 View
187 Download
12 Web of Science
10 Crossref

Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors: Myong Hoon Ihn, Duck-Woo Kim, Sukki Cho, Heung-Kwon Oh, Sanghoon Jheon, Kwhanmien Kim, Eun Shin, Hye Seung Lee, Jin-Haeng Chung, Sung-Bum Kang; Cancer Res Treat. 2017;49(1):104-115. Published online May 9, 2016; DOI: https://doi.org/10.4143/crt.2015.367

Abstract PDF PubReader ePub

Purpose
Prognostic factors in patients with pulmonary metastases (PM) from colorectal cancer (CRC) are still controversial. This study assessed oncologic outcomes and prognostic factors in patients with metachronous PM from CRC.
Materials and Methods
Between June 2003 and December 2011, 122 patients with CRC underwent curative resection of PM detected at least 4 months after CRC resection. Clinico-pathological factors selected from the prospectively maintained database were analyzed retrospectively.
Results
The median disease-free interval (DFI) between resection of the primary tumor and detection of PM was 22.0 months (range, 4 to 85 months). Solitary PM were detected in 77 patients (63.1%), with a median maximal tumor diameter of 12.0 mm (range, 2 to 70 mm). Of 52 patients who underwent mediastinal lymph node (LN) dissection, eight patients had LN involvement. Five-year overall survival and disease-free survival (DFS) rates after initial pulmonary metastasectomy were 66.4% and 50.9%, respectively. DFI, mediastinal LN involvement, and the number and distribution of PM were significantly prognostic factors for DFS. In multivariable analysis DFI ≥ 12 months, solitary lesion, and absence of mediastinal LN involvement were independently prognostic for DFS. Of the 122 patients, 48 patients (39.3%) developed recurrent PM a median 13.0 months after initial pulmonary metastasectomy. Recurrent DFI was independently prognostic of DFS in patients who underwent repeated pulmonary metastasectomy.
Conclusion
There is a potential survival benefit for patients with metachronous PM from CRC who undergo pulmonary metastasectomy, even those with recurrent PM. Pulmonary metastasectomy should be considered in selected patients, particularly those with longer DFI, solitary lesions, and absence of mediastinal LN involvement.

Citations

Citations to this article as recorded by

Outcomes and prognostic factors of repeat pulmonary metastasectomy
Ryu Kanzaki, Hirokazu Watari, Akiisa Omura, Sachi Kawagishi, Ryo Tanaka, Tomohiro Maniwa, Jiro Okami
Interdisciplinary CardioVascular and Thoracic Surgery.2024;[Epub] CrossRef
Development of a protocol for whole-lung in vivo lung perfusion-assisted photodynamic therapy using a porcine model
Khaled Ramadan, Tina Saeidi, Edson Brambate, Vanderlei Bagnato, Marcelo Cypel, Lothar Lilge
Journal of Biomedical Optics.2024;[Epub] CrossRef
circEIF3I Promotes Colorectal Cancer Metastasis by Regulating the miR‐328‐3p/NCAPH Axis
Yali Zhao, Yan He, Zhiyuan Xiao, Le Xin, Mingjing Deng, Mingxia Yao, Guan Huang
Molecular Carcinogenesis.2024;[Epub] CrossRef
Role of Pulmonary Metastasectomy in Colorectal Cancer
Zamaan Hooda, Michael Eisenberg, Mara B. Antonoff
Thoracic Surgery Clinics.2024;[Epub] CrossRef
Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer: a systematic review and meta-analysis
Andreas Gkikas, Christos Kakos, Savvas Lampridis, Peter J Godolphin, Davide Patrini
European Journal of Cardio-Thoracic Surgery.2023;[Epub] CrossRef
FUT2 inhibits the EMT and metastasis of colorectal cancer by increasing LRP1 fucosylation
Lingnan He, Zijun Guo, Weijun Wang, Shuxin Tian, Rong Lin
Cell Communication and Signaling.2023;[Epub] CrossRef
PET/MRI in colorectal and anal cancers: an update
Vetri Sudar Jayaprakasam, Semra Ince, Garima Suman, Pankaj Nepal, Thomas A. Hope, Raj Mohan Paspulati, Tyler J. Fraum
Abdominal Radiology.2023; 48(12): 3558. CrossRef
A review of surgery for lung metastasis from colorectal cancer
Yu-Kwang Lee, Mong-Wei Lin, Ke-Cheng Chen, Pei-Ming Huang, Shuenn-Wen Kuo, Jang-Ming Lee
Formosan Journal of Surgery.2023;[Epub] CrossRef
Long-term outcomes and early recurrence after resection for metachronous pulmonary metastases from colorectal cancer
Shintaro Hashimoto, Tetsuro Tominaga, Takashi Nonaka, Keisuke Noda, Soishiro Kiya, Toshio Shiraishi, Kaido Oishi, Yuma Takamura, Shoto Yamazaki, Masato Araki, Yorihisa Sumida, Takuro Miyazaki, Ryotaro Kamohara, Shigeyuki Morino, Keitaro Matsumoto, Akihiro
Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Survival and prognostic factors of isolated pulmonary metastases originating from colorectal cancer: An 8-year single-center experience
Ameera S. Balhareth, Abdullah S. AlQattan, Hassan M. Alshaqaq, Abdullah M. Alkhalifa, Alaa A. Al Abdrabalnabi, Muna S. Alnamlah, Deborah MacNamara
Annals of Medicine and Surgery.2022; 77: 103559. CrossRef
Long term survival after multiple microwave ablations for colorectal cancer lung metastases: A case report
Victoria T. Y Lee, Yueh-Hsin Lin, Derek Glenn, Suhrid Lodh, David L. Morris
Radiology Case Reports.2022; 17(6): 2038. CrossRef
A model to assess acute and delayed lung toxicity of oxaliplatin during in vivo lung perfusion
Khaled Ramadan, Bruno Gomes, Mauricio Pipkin, Mariola Olkowicz, Barbara Bojko, Arnaud Romeo Mbadjeu Hondjeu, Shaf Keshavjee, Thomas Waddell, Janusz Pawliszyn, Marcelo Cypel
The Journal of Thoracic and Cardiovascular Surgery.2021; 161(5): 1626. CrossRef
Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis
Junfeng Huang, Qing Zang, Yaokai Wen, Zhe Pan, Zhiyuan Yao, Mingkai Huang, Jiongqiang Huang, Jingsong Chen, Rongchang Wang
Critical Reviews in Oncology/Hematology.2021; 160: 103308. CrossRef
Systematic Review of Treatments for Colorectal Metastases in Elderly Patients to Guide Surveillance Cessation Following Hepatic Resection for Colorectal Liver Metastases
Edward Alabraba, Dhanny Gomez
American Journal of Clinical Oncology.2021; 44(5): 210. CrossRef
Determination of Optical Properties and Photodynamic Threshold of Lung Tissue for Treatment Planning of In Vivo Lung Perfusion Assisted Photodynamic Therapy
Khaled T. Ramadan, Christopher McFadden, Bruno Gomes, Fynn Schwiegelshohn, Rafaela V.P. Ribeiro, Harley H.L. Chan, Vaughn Betz, Marcelo Cypel, Lothar Lilge
Photodiagnosis and Photodynamic Therapy.2021; 35: 102353. CrossRef
Survival outcome of pulmonary metastasectomy among the patients with colorectal cancers
Oya Yıldız, Shute Ailia Dae, Alper Fındıkcıoglu, Fatih Kose
Revista da Associação Médica Brasileira.2021; 67(7): 1015. CrossRef
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer
Jiehua He, Ziqiang Chu, Wei Lai, Qiusheng Lan, Yujie Zeng, Daning Lu, Shaowen Jin, Heyang Xu, Pengwei Su, Dong Yin, Zhonghua Chu, Lu Liu
Journal of Hematology & Oncology.2021;[Epub] CrossRef
Vaccines for colorectal cancer: an update
Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh
Journal of Cellular Biochemistry.2019; 120(6): 8815. CrossRef
Surgical management of colorectal lung metastases
Joseph D. Phillips, Rian M. Hasson
Journal of Surgical Oncology.2019; 119(5): 629. CrossRef
Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice
S. Karim, S. Nanji, K. Brennan, C.S. Pramesh, C.M. Booth
European Journal of Surgical Oncology (EJSO).2017; 43(8): 1481. CrossRef
The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study
Hiroyuki Sakae, Hiromitsu Kanzaki, Junichiro Nasu, Yutaka Akimoto, Kazuhiro Matsueda, Masao Yoshioka, Masahiro Nakagawa, Shinichiro Hori, Masafumi Inoue, Tomoki Inaba, Atsushi Imagawa, Masahiro Takatani, Ryuta Takenaka, Seiyu Suzuki, Toshiyoshi Fujiwara,
British Journal of Cancer.2017; 117(11): 1607. CrossRef

10,435 View
198 Download
24 Web of Science
21 Crossref

Response Evaluation after Neoadjuvant Chemoradiation by Positron Emission Tomography-Computed Tomography for Esophageal Squamous Cell Carcinoma: Joon Suk Park, Joon Young Choi, Seung Hwan Moon, Yong Chan Ahn, Jeeyun Lee, Dohun Kim, Kwhanmien Kim, Young Mog Shim; Cancer Res Treat. 2013;45(1):22-30. Published online March 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.1.22

Abstract PDF PubReader ePub

PURPOSE
Parameters of positron emission tomography-computed tomography (PET-CT) were compared with the results of histopathologic examination in order to determine which can provide an objective indication of response after neoadjuvant chemoradiation for treatment of thoracic esophageal squamous cell carcinoma (SCC).
MATERIALS AND METHODS
Between August 2003 and January 2010, data on 25 patients who underwent neoadjuvant chemoradiation and subsequent resection for treatment of esophageal SCC were retrospectively reviewed. Changes in maximum standardized uptake value (DeltaSUVmax), metabolic tumor volume (DeltaMTV), and total lesion glycolysis (DeltaTLG) were analyzed by comparison with the histopathologic findings.
RESULTS
Pathologic complete remission (CR) for the main tumor was achieved in 11 patients. Postradiation esophagitis was observed in 10 patients. DeltaSUVmax of the main tumor was significantly greater in the CR group than in the partial response (PR) group (p=0.039), while DeltaMTV and DeltaTLG of the main tumor were not (p=0.141 and p=0.349, respectively). The cut-off DeltaSUVmax value for CR was estimated as 72.1%, indicating significantly better accuracy than visual interpretation (p=0.045). Of the 48 involved lymph nodes, DeltaSUVmax and DeltaMTV of lymph nodes were significantly greater in the CR group than in the PR group (p=0.045 and p=0.014, respectively), while DeltaTLG was not (p=0.063). The cut-off value of DeltaSUVmax for prediction of CR in lymph nodes was calculated as 50.67%.
CONCLUSION
PET-CT could be used for prediction of response to neoadjuvant treatment in thoracic esophageal SCC. DeltaSUVmax may be a more significant predictor for CR after neoadjuvant chemoradiation than DeltaTLG and DeltaMTV.

Citations

Citations to this article as recorded by

PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy
Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Kohei Kemuriyama, Yoshihiro Sasaki, Kazuhiro Imai, Eri Maeda, Yoshihiro Minamiya
Annals of Surgical Oncology.2022; 29(2): 1336. CrossRef
Prognostic factors associated with 18FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment
Wei-Hsiang Feng, Ying-Yi Chen, Yen‐Shou Kuo, Kuan-Hsun Lin, Yuan-Ming Tsai, Ti-Hui Wu, Hsu-Kai Huang, Tsai-Wang Huang
BMC Cancer.2022;[Epub] CrossRef
SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma
Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Yoshihiro Sasaki, Kazuhiro Imai, Yoshihiro Minamiya
World Journal of Surgical Oncology.2021;[Epub] CrossRef
18F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy
Seokmo Lee, Yunseon Choi, Geumju Park, Sunmi Jo, Sun Seong Lee, Jisun Park, Hye-Kyung Shim
Technology in Cancer Research & Treatment.2021;[Epub] CrossRef
Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Ben M. Eyck, Barbera D. Onstenk, Bo J. Noordman, Daan Nieboer, Manon C. W. Spaander, Roelf Valkema, Sjoerd M. Lagarde, Bas P. L. Wijnhoven, J. Jan B. van Lanschot
Annals of Surgery.2020; 271(2): 245. CrossRef
Utility of positron emission–computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation
Jiyun Lee, Joon Young Choi, Sung Won Lim, Myung-Ju Ahn, Keunchil Park, Jae Il Zo, Young Mog Shim, Dongryul Oh, Jong-Mu Sun
European Journal of Cardio-Thoracic Surgery.2020; 58(5): 1019. CrossRef
Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis
Didi J.J.M. de Gouw, Bastiaan R. Klarenbeek, Mitchell Driessen, Stefan A.W. Bouwense, Frans van Workum, Jurgen J. Fütterer, Maroeska M. Rovers, Richard P.G. ten Broek, Camiel Rosman
Journal of Thoracic Oncology.2019; 14(7): 1156. CrossRef
Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery
Won Kyung Cho, Dongryul Oh, Yong Chan Ahn, Young Mog Shim, Jae Ill Zo, Jong-Mu Sun, Myung-Ju Ahn, Keunchil Park
Oncotarget.2017; 8(2): 3542. CrossRef
Prognostic and Predictive Value of FDG-PET as an Aid in Oesophageal Cancer Management
Mian Xi, Steven H. Lin
EMJ Oncology.2017; : 78. CrossRef
Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma
Yoichi Hamai, Jun Hihara, Manabu Emi, Takaoki Furukawa, Ichiko Yamakita, Tomoaki Kurokawa, Morihito Okada
The Annals of Thoracic Surgery.2016; 102(4): 1132. CrossRef
PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma
Hui Yuan, Daniel K.H. Tong, Varut Vardhanabhuti, Simon Y.K. Law, Keith W.H. Chiu, Pek-Lan Khong
Nuclear Medicine Communications.2016; 37(9): 947. CrossRef
Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival
K. E. O’Sullivan, E. T. Hurley, J. P. Hurley
Gastroenterology Research and Practice.2015; 2015: 1. CrossRef
Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma
Arpit Chhabra, Leonard T Ong, Deborah Kuk, Geoffrey Ku, David Ilson, Yelena Y Janjigian, Abraham Wu, Heiko Schöder, Karyn A Goodman
British Journal of Cancer.2015; 113(12): 1658. CrossRef

12,728 View
55 Download
13 Crossref

Is There a Role of Postoperative Radiation Therapy in Completely Resected Stage I/II Thymic Epithelial Tumor?: Dongryul Oh, Yong Chan Ahn, Kwhanmien Kim, Jhingook Kim, Young Mog Shim, Jungho Han; Cancer Res Treat. 2012;44(3):166-172. Published online September 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.3.166

Abstract PDF PubReader ePub

PURPOSE
Retrospective analyses of patients with stage I-II thymic epithelial tumors (TET) who were treated with either surgery alone (S) or surgery plus postoperative radiation therapy (SRT) were conducted to evaluate the role of adjuvant radiation therapy (RT).
MATERIALS AND METHODS
A total of 110 stage I-II TET patients following complete resection were included in this study. Postoperative radiation therapy was recommended for those with aggressive histologic type and/or invasive features according to the surgeons' judgment during the operation. A median dose of 54.0 Gy (range, 44 to 60 Gy) focused on the primary tumor bed was administered to 57 patients (51.8%).
RESULTS
In all patients, the rates of overall survival, disease-specific survival, and disease-free survival at 10 years were 91.7%, 97.1%, and 95.8%, respectively. No significant differences in disease-specific survival (100% in the S group and 93.5% in the SRT group at 10 years, p=0.12) and disease-free survival (98.1% in the S group and 94.5% in the SRT group at 10 years, p=0.41) were observed between the treatment groups, although a significantly larger number of World Health Organization (WHO)-type B2-C (p<0.001) and Masaoka stage II (p=0.03) tumors were observed in the SRT group than in the S group. No local recurrence was observed in the SRT group. No grade 2 or greater RT-related toxicities were observed in the SRT group.
CONCLUSION
Excellent outcomes were achieved in patients with stage I-II TET who underwent complete resection. Considering excellent local control and low morbidity, adjuvant RT may be considered in high risk patients with WHO-type B2-C histology and Masaoka stage II.

Citations

Citations to this article as recorded by

Comparison of radiotherapy techniques in patients with thymic epithelial tumor who underwent postoperative radiotherapy
Hyunseok Lee, Dongryul Oh, Yong Chan Ahn, Hongryull Pyo, Kyungmi Yang, Jae Myoung Noh
Radiation Oncology Journal.2024; 42(1): 43. CrossRef
American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma
Stephen G. Chun, Andreas Rimner, Arya Amini, Joe Y. Chang, Jessica Donington, Martin J. Edelman, Yimin Geng, Matthew A. Gubens, Kristin A. Higgins, Puneeth Iyengar, Benjamin Movsas, Matthew S. Ning, Henry S. Park, George Rodrigues, Andrea Wolf, Charles B.
JAMA Oncology.2023; 9(7): 971. CrossRef
Case Reports: A role of postoperative radiation therapy in completely resected early stage intrathyroid thymic carcinoma: a case report and literature review of the diagnosis and treatment
Ailin Cui, Yaoqiang Du, Chunjie Hou, Lin Zhang, Litao Sun, Hongfeng He
Frontiers in Oncology.2023;[Epub] CrossRef
Patterns of Failure Following Postoperative Radiation Therapy Based on “Tumor Bed With Margin” for Stage II to IV Type C Thymic Epithelial Tumor
Kyung Hwa Lee, Jae Myoung Noh, Yong Chan Ahn, Dongryul Oh, Jhingook Kim, Young Mog Shim, Jung-ho Han
International Journal of Radiation Oncology*Biology*Physics.2018; 102(5): 1505. CrossRef
Survival Impact of Adjuvant Radiation Therapy in Masaoka Stage II to IV Thymomas: A Systematic Review and Meta-analysis
Yu Jin Lim, Eunji Kim, Hak Jae Kim, Hong-Gyun Wu, Jinchun Yan, Qin Liu, Shilpen Patel
International Journal of Radiation Oncology*Biology*Physics.2016; 94(5): 1129. CrossRef
A Review of the Place and Role of Radiotherapy in Thymoma
Dorothy C. Lombe, Branislav Jeremic
Clinical Lung Cancer.2015; 16(6): 406. CrossRef
Predictive SNPs for radiation-induced damage in lung cancer patients with radiotherapy: a potential strategy to individualize treatment
Qian Huang, Fangwei Xie, Xuenong Ouyang
The International Journal of Biological Markers.2015; 30(1): 1. CrossRef
Potential Role of Adjuvant Radiation Therapy in Cervical Thymic Neoplasm Involving Thyroid Gland or Neck
Jae Myoung Noh, Sang Yun Ha, Yong Chan Ahn, Dongryul Oh, Seung Won Seol, Young Lyun Oh, Joungho Han
Cancer Research and Treatment.2014; 47(3): 436. CrossRef

12,234 View
51 Download
8 Crossref

The Toxicity of Cisplatin Administered by Isolated Lung Perfusion in Dogs: Ho Seok I, Kwhanmien Kim, Jhingook Kim, Young Mog Shim, Jungho Han, Sung Sae Han; J Korean Cancer Assoc. 2000;32(6):1122-1132.

Abstract PDF: PURPOSE
This research was designed to evaluate the chronic effect of isolated lung perfusion (ILP) with cisplatin on dogs.
MATERIALS AND METHODS
Fifteen dogs were divided into three groups. Group I was in ILP without cisplatin, group II with 2.5 mg/kg and group III with 5.0 mg/kg of cisplatin for 30 minutes respectively. Serial blood samples were taken before and after ILP for quantitative analysis of serum lactate dehydrogenase (LDH) and blood urea nitrogen/creatinine (BUN/Cr). The specimens from the lung were obtained 2 weeks after ILP.
RESULTS
There were no statistic significant differences in LDH concentration according to the time interval among the groups. The LDH concentration peaked at 1 week after ILP and declined thereafter to the pre-ILP concentration. The concentration of BUN/Cr was in normal range. Histologic examination showed no pathologic change. No significant histopathologic differences were found in the pulmonary parenchyme and vasculature among the groups. All of the dogs survived without complication 2 weeks after ILP.
CONCLUSION
In ILP with cisplatin of 5.0 mg/kg in normal dog, the toxicity of cisplatin itself was not observed. With further study about the technique of ILP with cisplatin it would be effective to deliver high concentration of cisplatin into the target tissue minimizing lung damage.

2,310 View
13 Download

Limited Cytotoxic Effect of Adenoviral-mediated p53 Gene Transfer in Variable Non-small Cell Lung Cancer (NSCLC) Cell Lines: Jhingook Kim, Sook Hyun Lee, Eun Sung Hwang, Jong Sik Kim, Kwhanmien Kim, Je Ho Lee; J Korean Cancer Assoc. 1997;29(4):565-575.

Abstract PDF: PURPOSE
Cancer gene therapeutic strategy using p53 tumor suppresser gene have been suggested to be effective in many solid tumors including non-small cell lung cancer (NSCLC). To test generalized applicability, we tested a number of non-small cell lung cancer cell lines for their sensitivity to adenoviral-mediated wild-type p53 gene transfer.
MATERIALS AND METHOD
Replication-incompetent recombinant adenovirus encoding wild- type p53 (Avp53) under the control of the human cytomegalovirus (CMV) promoter was constructed and the cytotoxic effectiveness was evaluated in various NSCLC cell lines. Because 20 moi (multiplicity of infection; number of active virus particle/cell number) of Avp53 showed highly-effective cytotoxicity in p53-deleted cell lines (NCI-H1299, and NCI-H358), same amount was used for other cell lines.
RESULTS
Variable degree of cytotoxicity were observed in cell line with p53 mutation, but almost no effect were observed in those with will-type p53. Neither the infectivity of adenovirus, which was observed by x-gal stain after adenoviral mediated lac Z gene, nor the expression of p53 protein in infected cell, which was observed by western blot, was not the useful marker to expect the cytotoxic effect of Avp53. However, in responsive cell lines with Avp53, prominent expression of p21 protein, which was observed by western blot, was noticed.
CONCLUSION
In conclusion, adenoviral-mediated wild-type p53 transfer may not be applicable to every patient with non-small cell lung cancer, especially when the tumor has wild-type p53 gene. Better method to predict the effectiveness before application and strategy to widen the applicable extent is needed.

2,331 View
13 Download

First
Prev
Page of 1
Next
Last

Search